Current perspectives on the pathophysiology of schizophrenia, depression, and anxiety disorders

Medical Clinics of North America

Volumn 85, Issue 3, 2001, Pages 559-577

  Krystal, John H ^a,b,d   D'Souza, D Cyril ^a,b,d   Sanacora, Gerard ^a,b,d   Goddard, Andrew W ^a,c,d   Charney, Dennis S ^e  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Yale Medical Group   (United States)

^c Yale University School of Medicine   (United States)

^d VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^e NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANXIETY NEUROSIS; DEPRESSION; GENETIC SUSCEPTIBILITY; HIPPOCAMPUS; HUMAN; MENTAL STRESS; NEUROCHEMISTRY; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; SCHIZOPHRENIA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 0035039015     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0025-7125(05)70329-1     Document Type: Article

References (129)

1. Hypothalamic-pituitary-adrenal axis activity in panic disorder: 24-hour secretion of corticotropin and cortisol
2. The role of serotonin in the pathophysiology and treatment of schizophrenia
3. Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics
4. The role of corticotropin-releasing factor in depression and anxiety disorders
5. Serotonin neurons, neuroplasticity, and homeostasis of neural tissue
6. Substance P antagonists: The next breakthrough in treating depression?
7. Cerebral metabolic rates for glucose in mood disorders: Studies with positron emission tomography and fluorodeoxyglucose F 18
8. Deficits in small interneurons in prefrontal and cingulate cortices of schizophrenic and schizoaffective patients
9. Antidepressant effects of ketamine in depressed patients
10. fMRI reveals amygdala activation to human faces in social phobics
11. Early intervention in schizophrenia
12. A role for the serotonin system in the mechanism of action of antidepressant treatments: Preclinical evidence
13. CCK agonists and antagonists in clinical studies of panic and anxiety
14. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: Evidence from a novel positron emission tomography method
15. Functional magnetic resonance imaging of symptom provocation in obsessive-compulsive disorder
16. Positron emission tomography measurement of cerebral metabolic correlates of yohimbine administration in combat-related posttraumatic stress disorder
17. SPECT [I-123]iomazenil measurement of the benzodiazepine receptor in panic disorder
18. Noradrenergic mechanisms in stress and anxiety: I. Preclinical studies
19. Elevated CSF corticotropin-releasing factor concentrations in posttraumatic stress disorder
20. Hippocampal volume reduction in major depression
21. MRI-based measurement of hippocampal volume in patients with combat-related posttraumatic stress disorder
22. Deficits in short-term memory in posttraumatic stress disorder
23. Location of a major susceptibility locus for familial schizophrenia on chromosome 1q21-q22
24. Norepinephrine in depressive reactions: A review
25. Neurotransmitter aberrations in schizophrenia: New perspectives and therapeutic implications
26. Neuroendocrine regulation in depression: II. Discrimination of depressed from nondepressed patients
27. Functional hypofrontality and working memory dysfunction in schizophrenia
28. 2 challenge
29. A functional neuroanatomy of anxiety and fear: Implications for the pathophysiology and treatment of anxiety disorders
30. Receptor sensitivity and the mechanism of action of antidepressant treatment: Implications for the etiology and therapy of depression
31. Noradrenergic neuronal dysregulation in panic disorder: The effects of intravenous yohimbine and clonidine in panic disorder patients
32. Clinical improvement with fluoxetine therapy and noradrenergic function in patients with panic disorder
33. A receptor clustering results in enhanced anxiety and a bias for threat cues
34. Candidate gene study of eight GABA(A) receptor subunits in panic disorder
35. Two-dimensional proton echo-planar spectroscopic imaging of brain metabolic changes during lactate-induced panic
36. Proton magnetic resonance spectroscopy investigation of hyperventilation in subjects with panic disorder and comparison subjects
37. Neurotransmission in the rat amygdala related to fear and anxiety
38. Critical overview of current approaches to genetic mechanisms in schizophrenia research
39. Functional neuroimaging studies of depression: The anatomy of melancholia
40. Subgenual prefrontal cortex abnormalities in mood disorders
41. A molecular and cellular theory of depression
42. Neural plasticity to stress and antidepressant treatment
43. Physiological and behavioral responses to corticotropin-releasing factor administration: Is CRF a mediator of anxiety or stress responses?
44. Subcortical hyperintensities on brain magnetic resonance imaging: A comparison of normal and bipolar subjects
45. Use of buspirone in patients with generalized anxiety disorder and coexisting depressive symptoms: A meta-analysis of eight randomized, controlled studies
46. Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia
47. Principles of the pharmacotherapy of anxiety disorders
48. Effects of the serotonin reuptake inhibitor fluvoxamine on yohimbine-induced anxiety in panic disorder
49. Symptoms essential to the experience of sodium lactate-induced panic
50. 2 and hyperventilation in patients with panic disorder
51. Proliferation of granule cell precursors in the dentate gyrus of adult monkeys is diminished by stress
52. The economic burden of anxiety disorders in the 1990s
53. The impact of early adverse experiences on brain systems involved in the pathophysiology of anxiety and affective disorders
54. The revised monoamine theory of depression: A modulatory role for monoamines, based on new findings from monoamine depletion experiments in humans
55. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia
56. Cerebral structural abnormalities in obsessive-compulsive disorder: A quantitative morphometric magnetic resonance imaging study
57. m-Chlorophenylpiperazine as a probe of serotonin function
58. 2 receptor occupancy of clozapine, risperidone, and olanzepine in schizophrenia
59. Anna-Monika-Prize paper: Major depression and the environment: A psychiatric genetic perspective
60. Overview: A current perspective on twin studies of schizophrenia
61. Stressful life events and previous episodes in the etiology of major depression in women: An evaluation of the "kindling" hypothesis
62. Investigation of cholecystokinin system genes in panic disorder
63. Lifetime and 12-month prevalence of DSMIII-R psychiatric disorders in the United States: Results from the National Comorbidity Survey
64. The biological and adoptive families of adopted individuals who become schizophrenic: Prevalence of mental illness and other characteristics
65. False suffocation alarms, spontaneous panics, and related conditions: An integrative hypothesis
66. Distinct mechanism for antidepressant activity by blockade of central substance P receptors
67. Pharmacologic model psychoses
68. Glutamatergic contributions to cognitive dysfunction in schizophrenia
69. Human amygdala activation during conditioned fear acquisition and extinction: A mixed-trial fMRI study
70. Long-term behavioral and neuroendocrine adaptations to adverse early experience
71. Major depression and the basal ganglia
72. [3H]Neurotensin receptor densities in human postmortem brain tissue obtained from normal and schizophrenic persons: An autoradiographic study
73. Increased dopamine transmission in schizophrenia: Relationship to illness phases
74. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects
75. 5-HT1A receptor-effector system responsivity in panic disorder
76. Altered GABA neurotransmission and prefrontal cortical dysfunction in schizophrenia
77. The development of treatment resistance in patients with schizophrenia: A clinical and pathophysiologic perspective
78. EEG power modifications in panic disorder during a temporolimbic activation task: Relationships with temporal lobe clinical symptomatology
79. Agoraphobia, simple phobia, and social phobia in the National Comorbidity Survey
80. Decreased brain GABA(A)-benzodiazepine receptor binding in panic disorder: Preliminary results from a quantitative PET study
81. Lithium up-regulates the cytoprotective protein Bcl-2 in the CNS in vivo: A role for neurotrophic and neuroprotective effects in manic depressive illness
82. Limbic-cortical dysregulation: A proposed model of depression
83. Reciprocal limbic-cortical function and negative mood: Converging PET findings in depression and normal sadness
84. Stress and hippocampal plasticity
85. The profiles of clinical deterioration in schizophrenia
86. Benzodiazepine receptor: Demonstration in the central nervous system
87. Lower levels of nucleoside triphosphate in the basal ganglia of depressed subjects: A phosphorous-31 magnetic resonance spectroscopy study
88. Fear-potentiated startle in posttraumatic stress disorder
89. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments
90. Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus
91. Flumazenil provocation of panic attacks: Evidence for altered benzodiazepine receptor sensitivity in panic disorder
92. Glial reduction in the subgenual prefrontal cortex in mood disorders
93. Pronounced reduction of total neuron number in mediodorsal thalamic nucleus and nucleus accumbens in schizophrenics
94. The volume of the mediodorsal thalamic nucleus in treated and untreated schizophrenics
95. Structural brain imaging in schizophrenia
96. Psychoneuroendocrinology of depression: Hypothalamic-pituitary-adrenal axis
97. Search for schizophrenia susceptibility genes
98. Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression
99. Childhood-onset schizophrenia: Progressive ventricular change during adolescence
100. Regional cerebral blood flow measured during symptom provocation in obsessive-compulsive disorder using oxygen 15-labeled carbon dioxide and positron emission tomography
101. A positron emission tomographic study of simple phobic symptom provocation
102. A symptom provocation study of posttraumatic stress disorder using positron emission tomography and script-driven imagery
103. The application of positron emission tomography to the study of normal and pathologic emotions
104. The economic impact of schizophrenia
105. Lifetime prevalence of specific psychiatric disorders in three sites
106. Reduced benzodiazepine sensitivity in patients with panic disorder: Comparison with patients with obsessive-compulsive disorder and normal subjects
107. Reduced cortical gamma-aminobutyric acid levels in depressed patients determined by proton magnetic resonance spectroscopy
108. Why stress is bad for your brain
109. The catecholamine hypothesis of affective disorders: A review of supporting evidence
110. Low dopamine D(2) receptor binding potential in social phobia
111. Pharmacological agents acting at subtypes of metabotropic glutamate receptors
112. The reduced neuropil hypothesis: A circuit based model of schizophrenia
113. CSF neurotensin concentrations and antipsychotic treatment in schizophrenia and schizoaffective disorder
114. Hippocampal atrophy in recurrent major depression
115. The circumventricular organs form a potential neural pathway for lactate sensitivity: Implications for panic disorder
116. The anatomy of mood disorders-review of structural neuroimaging studies
117. Role of norepinephrine in the pathophysiology and treatment of posttraumatic stress disorder
118. Anatomical abnormalities in the brains of monozygotic twins discordant for schizophrenia
119. Dopamine reuptake site densities in patients with social phobia
120. Cerebral benzodiazepine receptor binding and distribution in generalized anxiety disorder: A fractal analysis
121. A repeat proton magnetic resonance spectroscopy study in social phobia
122. Modulation of anxiety and neuropeptide YY1 receptors by antisense oligodeoxynucleotides
123. Adrenergic receptor genes as candidate genes for panic disorder: A linkage study
124. Panic disorder and cardiovascular/cerebrovascular problems: Results from a community survey
125. The emotional counting Stroop paradigm: A functional magnetic resonance imaging probe of the anterior cingulate affective division
126. Maternal influenza, obstetric complications, and schizophrenia
127. Enhanced suppression of cortisol following dexamethasone administration in posttraumatic stress disorder